Zobrazeno 1 - 10
of 29
pro vyhledávání: '"L Yunquera Romero"'
Publikováno v:
Section 4: Clinical pharmacy services.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Section 7: Post Congress additions.
Publikováno v:
Eur J Hosp Pharm
Background It is considered that 30% to 50% of antibiotic prescriptions in the Emergency Department (ED) are inappropriate. Urinary tract infections (UTI) are one of the most commonly diagnosed infections in the ED. Purpose To assess the appropriaten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3727810281ecf13991f48680e32afd01
https://europepmc.org/articles/PMC7535381/
https://europepmc.org/articles/PMC7535381/
Autor:
A Henares López, I Márquez Gómez, I Muñoz Castillo, R Asensi Diez, LB Valiente de Santis, JM Reguera Iglesias, JM Salas Pérez, L Yunquera Romero
Publikováno v:
Eur J Hosp Pharm
Background Inappropriate prescription of antimicrobials has a significant epidemiological impact, since it favours the selection of strains of resistant microorganisms. Purpose Evaluate the changes in antimicrobials or route of administration by the
Publikováno v:
Drug information and pharmacotherapy.
Background New direct acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection achieve high rates of sustained virological response (SVR) which has changed the therapeutic strategy. Purpose To assess the effectiveness of the combination
Publikováno v:
Drug information and pharmacotherapy.
Background Fosfomycin trometamol is a broad spectrum antibiotic used in uncomplicated, low urinary tract infections (UTI) in women. Purpose To describe the use of fosfomycin trometamol in UTI in a third level hospital. Material and methods Hospitalis
Autor:
MJ Morales Lara, I Muñoz Castillo, L Yunquera Romero, C Ortega de la Cruz, P Conesa Zamora, C González Pérez-Crespo
Publikováno v:
Patient safety and risk management.
Background Drug related problems (DRP) are defined as negative clinical outcomes resulting from pharmacotherapy, which do not achieve therapy objectives or produce undesirable effects. They can be necessity, safety or effectiveness DRP. Purpose To me
Autor:
Aranzazu Linares-Alarcón, Manuel Ángel Castaño-Carracedo, L Yunquera-Romero, R Asensi-Diez, Juan Carlos del Rio-Valencia, I Muñoz-Castillo
Publikováno v:
Journal of AIDS & Clinical Research.
Introduction: Boosted protease inhibitor monotherapy (PI/r ) : Darunavir/ritonavir (DRV/r) or Lopinavir/ritonavir (LPV/r) monotherapy is only provided in the major treatment guidelines in pre-treated HIV patients to prevent toxicity associated with n
Autor:
L, Yunquera-Romero, R, Asensi-Díez, J C, Del Rio-Valencia, I, Muñoz-Castillo, M A, Castaño-Carracedo
Publikováno v:
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 29(6)
Ritonavir-boosted protease inhibitor (IP/r) monotherapy: darunavir/ritonavir (DRV/r) or lopinavir/ritonavir (LPV/r) monotherapy is only provided in the major treatment guidelines in pretreated patients to prevent toxicity associated with nucleoside/n